BioAge Labs to Present at Piper Sandler Healthcare Conference

In the crowded arena of metabolic medicine, BioAge Labs arrives with an unusual compass: the biology of human aging itself. The Emeryville-based biotech will present at a major New York healthcare conference in December, offering investors their clearest look yet at BGE-102, a drug candidate designed to quiet inflammatory pathways long associated with how bodies age and accumulate disease. With Phase 1 safety data expected before year's end, the company stands at one of those early thresholds where scientific premise must begin its long negotiation with clinical reality.